Expiration date: 01/2025
Specifications
Enisamium iodide
Form of release Tablets, film-coated 250 mg - 20 pcs per pack.
Store in a dry place
Store in a place protected from light
Keep away from children
Dosage form
Round biconvex tablets, coated with a yellow color; on the cross section, the core is from light yellow to yellow or yellow with a greenish tinge of color.
Composition
One tablet contains:
active substance: N-methyl-4-benzylcarbamidopyridinium iodide (enisamium iodide) (based on 100% anhydrous substance) - 250 mg.
excipients (core): lactose monohydrate (milk sugar) - 66.8 mg, microcrystalline cellulose (vivapur 101) - 20.0 mg, sucrose (refined sugar)-18.0 mg, povidone (polyvinylpyrrolidone low molecular weight medical or plasdon K - 17)-7.2 mg, copovidone (plasdon S - 630)-2.8 mg, crospovidone (polyplasdon XL - 10)-7.6 mg, talc - 3.8 mg, calcium stearate - 3.8 mg.
excipients (shell): Aquarius Prime BAN314047 Yellow-12 mg (hypromellose-7.92 mg, titanium dioxide-2.6874 mg, caprylate/caprylate (caprylic / caprine triglyceride) - 1.08 mg, iron oxide yellow dye-0.084 mg, iron oxide red dye-0.0006 mg, quinoline yellow dye-0.228 mg).
Special conditions
Caution should be exercised when prescribing the drug to patients with thyroid diseases, especially in hyperthyroidism.
Influence on the ability to drive vehicles and other mechanisms:
Taking the drug Nobazit ® does not affect the ability to drive vehicles and various mechanical equipment.
Drug interaction
Interaction with other drugs is not sufficiently studied.
Nobazit ® enhances the effect of antibacterial and immunomodulatory drugs. It is advisable to combine this drug with ascorbic acid and other vitamins. Also Nobazit ® can be administered concurrently with the use of recombinant interferon.
If you are using the above or other medications (including over-the-counter medications), consult your doctor before using Nobazit ® .
Pharmacodynamics
Nobazit ® - antiviral agent, a derivative of isonicotinic acid. Effectively suppresses the action of influenza viruses and other pathogens of acute respiratory viral infections (ARVI) due to the direct (inhibitory) effect on the process of virus penetration through the cell membrane.
It has interferogenic properties, increases the concentration of endogenous interferon (interferon alpha and interferon gamma) in the blood plasma by 3-4 times. Increases the body's resistance to viral infections.
Reduces acute clinical manifestations of viral intoxication, helps to reduce the duration of the disease.
Pharmacokinetics
After oral administration of enisamium, iodide quickly enters the blood, its maximum concentration in the blood is observed 2-2. 5 hours after use. Enisamium iodide and its metabolites circulate in the bloodstream for a long time (the half-life is 13.5-14 hours), are metabolized in the liver and are rapidly excreted from the tissues (the half-life is 2-3 hours). It is excreted by 90-95 % in the urine in the form of metabolites.
Indications
Treatment of influenza and other acute respiratory infections, including as part of complex therapy.
Contraindications
Hypersensitivity to any of the components of the drug. Lactase deficiency, lactose intolerance, glucose-galactose malabsorption. Sucrose/isomaltase deficiency, fructose intolerance. Children under 18 years of age, pregnancy, lactation. The presence of allergic reactions, regardless of the nature of the allergen in the anamnesis. Severe organic damage to the liver and kidneys.
Pregnancy and lactation:
Contraindicated during pregnancy and lactation.
Overdose
With an overdose of the drug, it is possible to increase the side effects described in the corresponding section. When they appear, gastric lavage, symptomatic treatment is performed.
Side effects
Allergic reactions: hypersensitivity reactions, including skin rashes, urticaria, angioedema, itching.
On the part of the digestive system: dryness and bitter taste in the mouth, swelling of the oral mucosa, hypersalivation, yellow staining of the tongue, nausea, vomiting, heartburn, abdominal pain, heaviness in the right hypochondrium, diarrhea, bloating.
From the respiratory system: shortness of breath, irritation of the throat.
In the post-registration period, the following adverse reactions were observed in isolated cases: headache, dizziness, weakness, fluctuation of blood pressure.
If you experience any of the side effects listed in the instructions, or if they worsen, or if you notice any other side effects not listed in the instructions, tell your doctor.
